Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial
Ying Cheng, Yun Fan, Yanqiu Zhao, Dingzhi Huang, Xingya Li, Peng Zhang, Mafei Kang, Nong Yang, Diansheng Zhong, Zhen Wang, Yan Yu, Yu Zhang, Jun Zhao, Tai Qin, Chenqi Chen, Shiangjiin Leaw, Wenjuan Zheng, Yong Song
Topics & Concepts
MedicineHazard ratioInternal medicinePlaceboInterquartile rangeEtoposideClinical endpointCarboplatinChemotherapyRandomized controlled trialConfidence intervalSurgeryGastroenterologyCisplatinPathologyAlternative medicineLung Cancer Research StudiesPARP inhibition in cancer therapyNeutropenia and Cancer Infections